Cerebrospinal fluid biomarkers in multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Neurobiology of Disease

• Publication date

  2009-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.nbd.2009.04.010PMID 19426803
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.

  2009cited by this paper
• Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets

  2008cited by this paper
• Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity.

  2008cited by this paper
• Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis

  2008cited by this paper
• Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis

  2008cited by this paper
• Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.

  2008cited by this paper
• CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients

  2008cited by this paper
• B cells and multiple sclerosis.

  2008cited by this paper
• Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis

  2008cited by this paper
• Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis.

  2008cited by this paper
• Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica

  2008cited by this paper
• Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis

  2008cited by this paper
• Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

  2008cited by this paper
• A multifactorial prognostic index in multiple sclerosis

  2008cited by this paper
• Multiple sclerosis‐related proteins identified in cerebrospinal fluid by advanced mass spectrometry

  2008cited by this paper
• Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis.

  2008cited by this paper
• Influence of oligoclonal IgM specificity in multiple sclerosis disease course

  2008cited by this paper
• Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases

  2008cited by this paper
• Lymphoid chemokines in chronic neuroinflammation

  2008cited by this paper
• Multiple sclerosis: Disease biomarkers as indicated by pathophysiology

  2007cited by this paper
• Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS

  2007cited by this paper
• Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

  2007cited by this paper
• Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b.

  2007cited by this paper
• Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord.

  2007cited by this paper
• Intrathecal IgM‐synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event

  2007cited by this paper
• Proteomic Analysis of Human Cerebral Endothelial Cells Activated by Multiple Sclerosis Serum and IFNβ-1b

  2007cited by this paper
• Cerebrospinal fluid proteome profile in multiple sclerosis

  2007cited by this paper
• Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis

  2007cited by this paper
• Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis

  2007cited by this paper
• Optical coherence tomography and disease subtype in multiple sclerosis

  2007cited by this paper
• Cerebrospinal Fluid IgM Index Correlates with Cranial MRI Lesion Load in Patients with Multiple Sclerosis

  2007cited by this paper
• Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry.

  2006cited by this paper
• Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.

  2006cited by this paper
• Proteomic-based biomarker discovery with emphasis on cerebrospinal fluid and multiple sclerosis.

  2006cited by this paper
• Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force

  2006cited by this paper
• Biomarkers in Multiple Sclerosis: Role of Antibodies

  2006cited by this paper
• Multiple Sclerosis Cerebrospinal Fluid Biomarkers

  2006cited by this paper
• Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients

  2006cited by this paper
• Oxidative stress and neurodegeneration: where are we now?

  2006cited by this paper
• Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis

  2006cited by this paper
• Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers

  2006cited by this paper
• Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis

  2006cited by this paper
• Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct

  2006cited by this paper
• Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

  2006cited by this paper
• The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis

  2006cited by this paper
• Clinically isolated syndromes

  2006cited by this paper
• Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.

  2006cited by this paper
• Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: Evidence that axonal loss is a substrate of MRI-detected atrophy

  2006cited by this paper
• Intrathecal sICAM-1 production in multiple sclerosis Correlation with triple dose Gd-DTPA MRI enhancement and IgG index

  2005cited by this paper
• Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study

  2005cited by this paper
• Biological markers in CSF and blood for axonal degeneration in multiple sclerosis.

  2005cited by this paper
• The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms.

  2005cited by this paper
• Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.

  2005cited by this paper
• Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.

  2005cited by this paper
• Evolution of brain-derived neurotrophic factor levels after autologous hematopietic stem cell transplantation in multiple sclerosis.

  2005cited by this paper
• Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis

  2005cited by this paper
• Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.

  2005cited by this paper
• Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease

  2005cited by this paper
• Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data

  2005cited by this paper
• Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

  2005cited by this paper
• Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.

  2005cited by this paper
• Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis.

  2004cited by this paper
• CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis

  2004cited by this paper
• Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients.

  2004cited by this paper
• The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system

  2004cited by this paper
• Cerebrospinal fluid levels of brain specific proteins in optic neuritis

  2004cited by this paper
• Selective and Antigen‐Dependent Effects of Myelin Degeneration on Central Nervous System Inflammation

  2004cited by this paper
• Proteomic analysis of multiple sclerosis cerebrospinal fluid

  2004cited by this paper
• Hyperphosphorylation and Aggregation of Tau in Experimental Autoimmune Encephalomyelitis*

  2004cited by this paper
• Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission

  2004cited by this paper
• Development of biomarkers in multiple sclerosis.

  2004cited by this paper
• Immunity to the Extracellular Domain of Nogo-A Modulates Experimental Autoimmune Encephalomyelitis1

  2004cited by this paper
• Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis

  2004cited by this paper
• Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients

  2004cited by this paper
• Immunologic factors in primary progressive multiple sclerosis

  2004cited by this paper
• C onversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fl uid and neurophysiological findings

  2003cited by this paper
• Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions.

  2003cited by this paper
• Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis

  2003cited by this paper
• Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system.

  2003cited by this paper
• Biological markers of the inflammatory phase of multiple sclerosis

  2003cited by this paper
• Intracranial arterial dolichoectasia and its relation with atherosclerosis and stroke subtype

  2003cited by this paper
• Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis.

  2003cited by this paper
• Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases

  2003cited by this paper
• Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes.

  2003cited by this paper
• A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

  2002cited by this paper
• Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis.

  2002cited by this paper
• Brain-derived neurotrophic factor in patients with multiple sclerosis.

  2002cited by this paper
• Multiple sclerosis.

  2002cited by this paper
• Multiple Sclerosis as a By-Product of the Failure to Sustain Protective Autoimmunity: A Paradigm Shift

  2002cited by this paper
• Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

  2002cited by this paper
• Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.

  2002cited by this paper
• Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis

  2002cited by this paper
• Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients.

  2001cited by this paper
• Determination of soluble ICAM-1 and TNFalphaR in the cerebrospinal fluid and serum levels in a population of Brazilian patients with relapsing-remitting multiple sclerosis.

  2001cited by this paper
• Increased nitric oxide products in CSF in primary progressive MS may reflect brain atrophy

  2001cited by this paper
• Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica.

  2001cited by this paper
• Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

  2001cited by this paper
• Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count.

  2000cited by this paper
• Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

  2000cited by this paper
• Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases.

  2000cited by this paper

• Large-scale proteomics across neurological disorders uncovers biomarker panel and targets in multiple sclerosis.

  2026cites this paper
• Prominosomes - a particular class of extracellular vesicles containing prominin-1/CD133?

  2025cites this paper
• Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers

  2025cites this paper
• 3D protein structure of chemokines in multiple sclerosis

  2025cites this paper
• Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis

  2024cites this paper
• A sex‐dependent algorithm including kappa free light chain for multiple sclerosis diagnosis

  2024influential citation
• Automated Glycan-Bead Coupling for High Throughput, Highly Reproducible Anti-Glycan Antibody Analysis.

  2023cites this paper
• Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure

  2022cites this paper
• Optic Neuritis in Multiple Sclerosis—A Review of Molecular Mechanisms Involved in the Degenerative Process

  2022cites this paper
• Metabolomics as a promising tool for improving understanding of multiple sclerosis: A review of recent advances

  2022cites this paper
• Literatur

  2022cites this paper
• Recent Technological Developments in the Diagnosis and Treatment of Cerebral Edema

  2021cites this paper
• Advances for the Development of In Vitro Immunosensors for Multiple Sclerosis Diagnosis

  2021cites this paper
• The Anaesthetic Biobank of Cerebrospinal fluid: a unique repository for neuroscientific biomarker research

  2021cites this paper
• Neurodegeneration: Diagnosis, Prevention, and Therapy

  2021cites this paper
• Exploring the genomic and transcriptomic landscape of immune cells in multiple sclerosis : towards better biomarkers, diagnosis and treatment.

  2020cites this paper
• CSF biomarkers in multiple sclerosis: beyond neuroinflammation

  2020cites this paper
• Brain Homogenate Decoys for Antigen-Specific Cell Amplification.

  2020cites this paper
• Immunmediierte Erkrankungen des Nervensystems

  2020cites this paper
• Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis

  2019cites this paper
• Biomarkers in Multiple Sclerosis.

  2019cites this paper
• CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort

  2019cites this paper
• Relevance of KFLC quantification to differentiate clinically isolated syndrome from multiple sclerosis at clinical onset.

  2018cites this paper
• 46 – Multiple Sclerosis

  2018cites this paper
• Kappa free light chains in cerebrospinal fluid to identify patients with oligoclonal bands

  2018cites this paper
• In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study

  2018cites this paper
• Spatial and molecular changes of mouse brain metabolism in response to immunomodulatory treatment with teriflunomide as visualized by MALDI-MSI

  2018cites this paper
• GFAP in early multiple sclerosis: A biomarker for inflammation.

  2017cites this paper
• Metabolomic signatures associated with disease severity in multiple sclerosis

  2017cites this paper
• Biomarkers of Multiple Sclerosis and Their Modulation by Natural Products

  2017cites this paper
• Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients

  2017cites this paper
• Biomarker Development in Chronic Inflammatory Diseases

  2017cites this paper
• New approach in cervical spine compression

  2017cites this paper
• McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity

  2016cites this paper
• B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis

  2016cites this paper
• Anoctamin 2 identified as an autoimmune target in multiple sclerosis

  2016cites this paper
• Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases

  2016cites this paper
• Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward

  2015cites this paper
• Methods for Biomarker Analysis

  2015cites this paper
• University of Birmingham Translational biomarkers of neurotoxicity

  2015cites this paper
• Kapitel 7 – Krankheitsverlauf und Prognose

  2015cites this paper
• Kapitel 11 – Marker des Liquor cerebrospinalis und des Blutes im Überblick

  2015cites this paper
• Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients.

  2015cites this paper
• The Role of Oxidative Stress in Neurodegenerative Diseases

  2015cites this paper
• Biomarqueurs utilisés pour le diagnostic et la prise en charge de maladies neuro-immunologiques

  2015cites this paper
• Biomarkers for phase switches in multiple sclerosis

  2015cites this paper
• No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients

  2015cites this paper
• Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel

  2015cites this paper
• Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?

  2015cites this paper
• Elevated CNS Inflammation in Patients with Preclinical Alzheimer's Disease

  2014cites this paper
• Biomarkers in multiple sclerosis: an update for 2014.

  2014cites this paper
• Natalizumab versus Interferon β-1b to prevent CDMS in patients with CIS and poor prognostic factors: research protocol

  2014cites this paper
• A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis

  2014cites this paper
• Biomarcadores en la esclerosis múltiple:: puesta al día 2014

  2014cites this paper
• High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis.

  2014cites this paper
• Matrix Metalloproteinase Inhibition Lowers Mortality and Brain Injury in Experimental Pneumococcal Meningitis

  2014cites this paper
• Biomarkers of treatment response in multiple sclerosis

  2014cites this paper
• Metabolomics and the diagnosis of human diseases--a guide to the markers and pathophysiological pathways affected.

  2014cites this paper
• Cyclic phosphatidic acid treatment suppress cuprizone-induced demyelination and motor dysfunction in mice.

  2014cites this paper
• Ten years of proteomics in multiple sclerosis

  2014cites this paper
• Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis

  2014cites this paper
• Scientific production

  2014cites this paper
• Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis.

  2014cites this paper
• Clinical Bioinformatics: A New Emerging Science of Biomarker Development

  2014cites this paper
• Diffusion Tensor Imaging in NAWM and NADGM in MS and CIS: Association with Candidate Biomarkers in Sera

  2013cites this paper
• Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis

  2013cites this paper
• Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.

  2013cites this paper
• Identification of autoantigens in body fluids by combining pull-downs and organic precipitations of intact immune complexes with quantitative label-free mass spectrometry.

  2013cites this paper
• Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis

  2013cites this paper
• Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis

  2013cites this paper
• The utility of cerebrospinal fluid analysis in patients with multiple sclerosis

  2013cites this paper
• 25-hydroxyvitamin D3 concentration in serum and cerebrospinal fluid of patients with remitting-relapse multiple sclerosis.

  2013cites this paper
• Molecular Biomarkers in Multiple Sclerosis

  2013cites this paper
• [Biomarkers in multiple sclerosis (a review and experimental data)].

  2013cites this paper
• Recent progress in omics-driven analysis of MS to unravel pathological mechanisms

  2013cites this paper
• Investigation of the pathophysiology of progression in multiple sclerosis: studies on cerebrospinal fluid biomarkers

  2013cites this paper
• Biomarkers in Multiple Sclerosis: An Up-to-Date Overview

  2013cites this paper
• Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis.

  2013cites this paper
• Clinically isolated syndromes.

  2012cites this paper
• Cerebral white matter changes in patients with cognitive impairment - clinical and pathophysiological aspects

  2012cites this paper
• The cyclooxygenase‐2 pathway via the PGE2 EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone‐induced demyelination

  2012cites this paper
• Lipocalin 2 is present in the EAE brain and is modulated by natalizumab

  2012cites this paper
• NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review.

  2012cites this paper
• Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis

  2012cites this paper
• Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis.

  2012cites this paper
• Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.

  2012cites this paper
• Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis

  2012cites this paper
• YPING IN MULTIPLE SCLEROSIS

  2012cites this paper
• Biological Markers in the Diagnosis of Multiple Sclerosis

  2012cites this paper
• Early neurodegenerative changes in a rat model of multiple sclerosis

  2012cites this paper
• Multiple Sclerosis Prevalence in New Zealand: Effects of Latitude and UV

  2012cites this paper
• Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis.

  2012cites this paper
• Cerebrospinal Fluid and Blood Biomarkers of Neuroaxonal Damage in Multiple Sclerosis

  2011cites this paper
• MRM assay for quantitation of complement components in human blood plasma - a feasibility study on multiple sclerosis.

  2011cites this paper
• Metabolic profiling in multiple sclerosis and other disorders by quantitative analysis of cerebrospinal fluid using nuclear magnetic resonance spectroscopy.

  2011cites this paper
• Metabolic profiling in multiple sclerosis and other disorders by quantitative analysis of cerebrospinal fluid using nuclear magnetic resonance spectroscopy.

  2011cites this paper
• Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients

  2011cites this paper
• Die Relevanz einer B-Zell-abhängigen Immunpathologie für die Multiple Sklerose

  2011cites this paper
• Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121

  2011cites this paper
• Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.

  2011cites this paper